Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP-7041 in healthy volunteers
NCT02914353Phase 1Completed
- Sponsor
- eXIthera
- Start
- Jul 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of frunexian in venous thromboembolism (VTE) (4 arms), sponsored by eXIthera. Primary endpoints: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 following a single IV bolus of EP-7041 at 30 days and Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 following a continuous IV infusion of EP-7041 administered over 5 days at 30 days. Started Jul 2016; status: completed.
02
Drugs
frunexian
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02914353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914353.